Monoparamunity inducers based on attenuated rabbit myxomaviruses

Abstract

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

1 - 48 . (canceled) 
     
     
         49 . A pharmaceutical preparation suitable for use in a human,
 wherein the pharmaceutical preparation is prepared by purifying an attenuated myxomavirus, inactivating the myxomavirus, and lyophilizing the inactivated virus to generate a pharmaceutical preparation suitable for use in a human.   
     
     
         50 . The pharmaceutical preparation of  claim 49 , wherein the pharmaceutical preparation is a buccal tablet. 
     
     
         51 . The pharmaceutical preparation of  claim 50 , wherein the tablet comprises Kollidon 25, urea, sorbitol, polyethylene glycol 6000, potassium dihydrogenphosphate, disodium hydrogenphosphate, tyrospirol tablet essence, or magnesium stearate. 
     
     
         52 . The pharmaceutical preparation of  claim 49 , wherein the pharmaceutical preparation is in dry form. 
     
     
         53 . The pharmaceutical preparation of  claim 49 , wherein the pharmaceutical preparation is in liquid form. 
     
     
         54 . The pharmaceutical preparation of  claim 53 , wherein the lyophilized, inactivated virus is resuspended in water. 
     
     
         55 . The pharmaceutical preparation of  claim 49 , wherein the pharmaceutical preparation is suitable for human parenteral injection. 
     
     
         56 . The pharmaceutical preparation of  claim 49 , wherein the pharmaceutical preparation is a cream for application to the human skin. 
     
     
         57 . The pharmaceutical preparation of  claim 49 , wherein the myxomavirus is purified by centrifugation. 
     
     
         58 . The pharmaceutical preparation of  claim 49 , wherein the myxomavirus is inactivated by treatment with beta-propiolactone. 
     
     
         59 . The pharmaceutical preparation of  claim 58 , wherein the betapropiolactone is at a concentration of 0.01-1.0% 
     
     
         60 . The pharmaceutical preparation of  claim 58 , wherein the betapropiolactone is at a concentration of 0.05%. 
     
     
         61 . The pharmaceutical preparation of  claim 49 , wherein the myxomavirus is the attenuated myxomavirus as deposited at ECACC under No. 03121801. 
     
     
         62 . The pharmaceutical preparation of  claim 49 , wherein the myxomavirus is a myxomavirus that has lost the receptor properties of one or more myxomavirus interferon receptor, one or more myxomavirus tumor necrosis factor receptor, and one or more myxomavirus interleukin receptor. 
     
     
         63 . The pharmaceutical preparation of  claim 49 , wherein the myxomavirus is a myxomavirus that has lost the receptor properties of the myxomavirus cytokine receptors IFNα-R, IFNγ-R, TNF-R, IL-1-R, IL-2-R, IL-6-R, and IL-12-R. 
     
     
         64 . A pharmaceutical preparation suitable for use in a human comprising a purified, attenuated, inactivated myxomavirus. 
     
     
         65 . The pharmaceutical preparation of  claim 64 , wherein the myxomavirus is lyophilized. 
     
     
         66 . The pharmaceutical preparation of  claim 64 , wherein the myxomavirus is inactivated by treatment with beta-propiolactone. 
     
     
         67 . The pharmaceutical preparation of  claim 64 , wherein the pharmaceutical preparation is a buccal tablet. 
     
     
         68 . The pharmaceutical preparation of  claim 64 , wherein the myxomavirus is a myxomavirus that has lost the receptor properties of one or more myxomavirus interferon receptor, one or more myxomavirus tumor necrosis factor receptor, and one or more myxomavirus interleukin receptor. 
     
     
         69 . The pharmaceutical preparation of  claim 64 , wherein the myxomavirus is a myxomavirus that has lost the receptor properties of the myxomavirus cytokine receptors IFNα-R, IFNγ-R, TNF-R, IL-1-R, IL-2-R, IL-6-R, and IL-12-R.